Ovulation stimulation and induction

Area of Science:

• Reproductive Endocrinology
• Infertility Treatment
• Hormonal Imbalance Management

Background:

• Anovulation requires careful hormonal evaluation to guide effective treatment.
• Treatment selection prioritizes safety and cost-effectiveness for specific indications.
• Achieving pregnancy rates comparable to normally ovulating women is a key therapeutic goal, barring FSH elevation.

Purpose of the Study:

• To outline a strategic approach for managing anovulatory infertility.
• To detail the first-line and subsequent therapies for various anovulatory states.
• To highlight the role of specific medications like bromocriptine, clomiphene citrate, menotropins, and GnRH analogs.

Main Methods:

• Hormonal assessment including gonadotropins, prolactin, and thyroid function.
• Pharmacological interventions based on diagnosis: bromocriptine for hyperprolactinemia, clomiphene citrate for normoestrogenic anovulation.
• Sequential treatment escalation involving menotropins and pulsatile GnRH for resistant cases, with consideration for GnRH analog pretreatment.

Main Results:

• Bromocriptine successfully restores ovulation in over 90% of hyperprolactinemic women.
• Clomiphene citrate is effective for normoestrogenic anovulation, with menotropin therapy indicated after six failed cycles.
• Menotropins and pulsatile GnRH are primary treatments for hypogonadotropic anovulation, potentially enhanced by GnRH analogs.
• GnRH analogs improve outcomes in hMG-assisted reproductive technologies by preventing premature luteinization.

Conclusions:

• A stepwise, evidence-based approach to anovulatory infertility treatment optimizes outcomes.
• Personalized therapy selection based on hormonal profiles and treatment response is crucial.
• Advanced reproductive technologies benefit from GnRH analog use to improve success rates.